Asylia Diagnostics

Foundation date



#Biotechnology / R&D Services


Therapeutic areas

At Asylia Diagnostics we are building a technology platform that will permit a quick and efficient high-resolution profiling of tumor microenvironment, different immune cells and their subtypes, and cell signaling. With the right data at hand, it will unlock an opportunity to discover novel biomarkers and modes of action for investigational drugs.

Upcoming events

Latest news

  • argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia

    21 hours ago

  • Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion

    Wednesday November 22nd 2023

  • argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis

    Thursday November 16th 2023